Drugs Made In America Acquisition DMIIR
NASDAQ DMIIR
$0.07 -0.01 (-7.04%)
As of: Sep 2, 2026 · 12:48 PM EDT

Drugs Made In America Acquisition (DMIIR) Profit After Tax (2025 - 2026)

Drugs Made In America Acquisition (DMIIR) posted quarterly Profit After Tax of $4.3 million for Q4 2025, up 9482.14% quarter-over-quarter from -$46158.0 in Q3 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Drugs Made In America Acquisition (DMIIR) Profit After Tax (2025 - 2026) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has reported Profit After Tax for 1 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Cluster Group Holdings 8.00 Bn 8.00 Bn - -8,222.00
2 Agriculture & Natural Solutions Acquisition 853.42 Mn 853.17 Mn - 3.03 Mn
3 K&F Growth Acquisition 836.15 Mn 836.15 Mn - 2.48 Mn
4 Armada Acquisition 665.67 Mn 665.62 Mn - 1.63 Mn
5 Pioneer Acquisition I 652.74 Mn 652.27 Mn - 2.13 Mn
6 Oxley Bridge Acquisition 652.11 Mn 652.11 Mn - 2.12 Mn
7 Titan Acquisition 651.43 Mn 941.85 Mn - 2.07 Mn
8 GSR IV Acquisition 622.22 Mn 622.22 Mn - 1.76 Mn
9 Launch One Acquisition 618.70 Mn 618.70 Mn - 1.60 Mn
10 Drugs Made In America Acquisition 5.10 Mn 5.10 Mn - 4.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.40 Mn
Dec 31, 2025 4.33 Mn
Sep 30, 2025 -46,158.00